Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

被引：36
|
作者：
Lee, Sung Won [1 ,2 ]
Choi, Jonggi [3 ]
Kim, Seung Up [4 ,5 ]
Lim, Young-Suk [3 ]
机构：
[1] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Catholic Univ, Liver Res Ctr, Seoul, South Korea
[3] Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea
[4] Yonsei Univ, Inst Gastroenterol, Dept Internal Med, Coll Med, Seoul, South Korea
[5] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2021年 / 27卷 / 03期
关键词：
Entecavir; Tenofovir; Hepatitis B; Carcinoma; Hepatocellular; Efficacy; Outcome; DISOPROXIL FUMARATE; RISK; CIRRHOSIS;
D O I：
10.3350/cmh.2021.0179
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.
引用
收藏
页码：402 / 412
页数：11
相关论文
共 50 条
  • [41] Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis
    Tony, Sara M.
    Shaaban, Mohamed E. A.
    Mohamed, Ahmed I. M.
    Abdelrahim, Mohamed E. A.
    BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES, 2022, 11 (01)
  • [42] Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma
    Mar Riveiro-Barciela
    David Tabernero
    José L. Calleja
    Sabela Lens
    María L. Manzano
    Francisco Gea Rodríguez
    Javier Crespo
    Belén Piqueras
    Juan M. Pascasio
    Carmen Comas
    Maria L. Gutierrez
    Alberto Aguirre
    Emilio Suárez
    Javier García-Samaniego
    Miguel Rivero
    Doroteo Acero
    Miguel Fernandez-Bermejo
    Diego Moreno
    Pilar Sánchez-Pobre
    Beatriz de Cuenca
    J. J Moreno-Palomares
    Rafael Esteban
    Maria Buti
    Digestive Diseases and Sciences, 2017, 62 : 784 - 793
  • [43] Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis
    Min Li
    Tingting Lv
    Shanshan Wu
    Wei Wei
    Xiaohai Wu
    Xiaojuan Ou
    Hong Ma
    Shein-Chung Chow
    Yuanyuan Kong
    Hong You
    Jidong Jia
    Hepatology International, 2020, 14 : 105 - 114
  • [44] Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection
    Zhang, Min
    Wang, Dexin
    Liu, Haidong
    Li, Hui
    INFECTIOUS AGENTS AND CANCER, 2018, 13
  • [45] Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis
    Li, Min
    Lv, Tingting
    Wu, Shanshan
    Wei, Wei
    Wu, Xiaohai
    Ou, Xiaojuan
    Ma, Hong
    Chow, Shein-Chung
    Kong, Yuanyuan
    You, Hong
    Jia, Jidong
    HEPATOLOGY INTERNATIONAL, 2020, 14 (01) : 105 - 114
  • [46] Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
    Chang, Jin Won
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Seo, Yeon Seok
    Lee, Han Ah
    Kim, Mi Na
    Lee, Yu Rim
    Hwang, Seong Gyu
    Rim, Kyu Sung
    Um, Soon Ho
    Tak, Won Young
    Kweon, Young Oh
    Park, Soo Young
    Kim, Seung Up
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (01) : 95 - 104
  • [47] Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir
    Yu, Jung Hwan
    Suh, Young Ju
    Jin, Young-Joo
    Heo, Nae-Yun
    Jang, Ji Woong
    You, Chan Ran
    An, Hyun Young
    Lee, Jin-Woo
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (07) : 865 - 872
  • [48] Comparison of the Efficacy of Entecavir and Tenofovir in Chronic Hepatitis B
    Guzelbulut, Fatih
    Ovunc, Ayse Oya Kurdas
    Cetinkaya, Zuleyha Akkan
    Senates, Ebubekir
    Gokden, Yasemin
    Salturk, Ayca Gokcen Degirmenci
    Sezikli, Mesut
    Ozkara, Selvinaz
    Cetinkaya, Fuat
    HEPATO-GASTROENTEROLOGY, 2012, 59 (114) : 477 - 480
  • [49] Use of tenofovir disoproxil fumarate is associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B
    Choi, Won-Mook
    Choi, Jonggi
    HEPATOMA RESEARCH, 2021, 7
  • [50] Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis
    Shahzil, Muhammad
    Chaudhary, Ammad Javaid
    Kashif, Talha
    Qureshi, Ali Akram
    Muhammad, Anza
    Khan, Faiza
    Faisal, Muhammad Saad
    Khaqan, Muhammad Ali
    Ali, Hassam
    Dababneh, Yara
    Moonka, Dilip
    JGH OPEN, 2024, 8 (11):
12345